Conditions comorbid to autism spectrum disorders
Autism spectrum disorders (ASD) are developmental disorders that begin in early childhood, persist throughout adulthood, and affect three crucial areas of development: communication, social interaction and restricted patterns of behavior. There are many conditions comorbid to autism spectrum disorders such as fragile X syndrome and epilepsy.
In medicine and in psychiatry, comorbidity is the presence of one or more additional conditions co-occurring with the primary one, or the effect of such additional disorders. About 10–15% of autism cases have an identifiable Mendelian (single-gene) condition, chromosome abnormality, or other genetic syndrome, and ASD is associated with several genetic disorders, perhaps due to an overlap in genetic causes.
Distinguishing between ASDs and other diagnoses can be challenging because the traits of ASDs often overlap with symptoms of other disorders and the characteristics of ASDs make traditional diagnostic procedures difficult.
- 1 Comorbid conditions
- 1.1 Mitochondrial diseases
- 1.2 Anxiety
- 1.3 Attention-deficit hyperactivity disorder
- 1.4 Neuropathies
- 1.5 Bipolar disorder
- 1.6 Bowel disease
- 1.7 Depression
- 1.8 Developmental coordination disorder
- 1.9 Epilepsy
- 1.10 Fragile X syndrome
- 1.11 Gender dysphoria
- 1.12 Intellectual disability
- 1.13 Neuroinflammation and immune disorders
- 1.14 Abnormal redox metabolism
- 1.15 Abnormal folate metabolism
- 1.16 Vitamin deficiencies
- 1.17 Abnormalities of melatonin and circadian rhythm
- 1.18 Nonverbal learning disorder
- 1.19 Obsessive-compulsive disorder
- 1.20 Psychosis and schizophrenia
- 1.21 Tourette syndrome
- 1.22 Sensory problems
- 1.23 Tinnitus
- 1.24 Tuberous sclerosis
- 1.25 Sleep disorders
- 1.26 Other mental disorders
- 2 See also
- 3 References
The central player in bioenergetics is the mitochondrion. Mitochondria produce about 90% of cellular energy, regulate cellular redox status, produce ROS, maintain Ca2+ homeostasis, synthesize and degrade high-energy biochemical intermediates, and regulate cell death through activation of the mitochondrial permeability transition pore (mtPTP). When they fail, less and less energy is generated within the cell. Cell injury and even cell death follow. If this process is repeated throughout the body, whole organ systems begin to fail.
Mitochondrial diseases are a heterogeneous group of disorders that can affect multiple organs with varying severity. Symptoms may be acute or chronic with intermittent decompensation. Neurological manifestations include encephalopathy, stroke, cognitive regression, seizures, cardiopathies (Cardiac conduction defects, HHD, Cardiomyopathy, ect...), diabetes, visual and hearing loss, organ failure, neuropathic pain and peripheral neuropathy.
The prevalence estimates of mitochondrial disease and dysfunction across studies ranging from about 5 to 80%. This may be, in part, due to the unclear distinction between mitochondrial disease and dysfunction. Mitochondrial diseases are difficult to diagnose and have become better known and detected. Studies indicating the highest rates of mitochondrial diagnosis are usually the most recent.
Some drugs are toxic to mitochondria. These can trigger or aggravate dysfunctions or mitochondrial diseases.
- Antiepileptics :
Valproic acid (also used in various other indications) and phenytoin are the most toxic. Phenobarbital, carbamazepine, oxcarbazepine, ethosuximide, zonisamide, topiramate, gabapentin and vigabatrin are also.
- Other types of drugs :
Corticosteroids (cortisone), accutane (isotretinoin) and other vitamin A derivatives, barbiturates, certain antibiotics, propofol, volatile anesthetics, non-depolarizing muscle relaxants, some local anesthetics, statins, fibrates, glitazones, beta blockers, biguanides, amiodarone, some chemotherapies, some neuroleptics, nucleoside reverse transcriptase inhibitors and various other drugs.
Anxiety disorders are common among children and adults with ASD. Symptoms are likely affected by age, level of cognitive functioning, degree of social impairment, and ASD-specific difficulties. Many anxiety disorders, such as social anxiety disorder and generalized anxiety disorder, are not commonly diagnosed in people with ASD because such symptoms are better explained by ASD itself, and it is often difficult to tell whether symptoms such as compulsive checking are part of ASD or a co-occurring anxiety problem. The prevalence of anxiety disorders in children with ASD has been reported to be anywhere between 11% and 84%; the wide range is likely due to differences in the ways the studies were conducted.
Attention-deficit hyperactivity disorder
Previously, the diagnosis manual DSM-IV did not allow the co-diagnosis of ASD and attention-deficit hyperactivity disorder (ADHD). However, following years of clinical research, the most recent publication (DSM-5) in 2013 removed this prohibition of co-morbidity. Thus, individuals with autism spectrum disorder may also have a diagnosis of ADHD, with the modifiers of inattentive, hyperactive, combined-type, or not otherwise specified. Clinically significant symptoms of these two conditions commonly co-occur, and children with both sets of symptoms may respond poorly to standard ADHD treatments. Individuals with autism spectrum disorder may benefit from additional types of medications.
The prevalence of peripheral neuropathies would be significantly increased in ASD. Peripheral neuropathies may be asymptomatic. Peripheral neuropathy is a common manifestation of mitochondrial diseases and polyneuropathies would be relatively common. Neuropathies could also be caused by other features of ASD.
Bipolar disorder, or manic-depression, is itself often claimed to be comorbid with a number of conditions, including autism. Autism includes some symptoms commonly found in mood and anxiety disorders.
Some individuals with autism also have gastrointestinal (GI) symptoms, but there is a lack of published rigorous data to support the theory that children with autism have more or different GI symptoms than usual. It has been claimed that up to fifty percent of children with autism experience persistent gastrointestinal tract problems, ranging from mild to moderate degrees of inflammation in both the upper and lower intestinal tract. This has been described as a syndrome, autistic enterocolitis, by Dr. Andrew Wakefield; this diagnostic terminology has been rejected by medical experts as pseudoscience. His study, which included a total of 12 children, implied that the MMR vaccine causes autism and autistic enterocolitis. The Lancet eventually retracted Wakefield's study. Furthermore, the General Medical Council of the UK subsequently revoked Wakefield's license to practice medicine as a result of the study, citing Wakefield's numerous violations of ethical principles, including failure to disclose financing from lawyers who were preparing a suit against vaccine manufacturers. Constipation, often with overflow, or encopresis, is often associated with developmental disorders in children, and is often difficult to resolve, especially among those with behavioral and communication problems.
Major depressive disorder has been shown by several studies to be one of the most common comorbid conditions in those with ASD, and is thought to develop and occur more in high-functioning individuals during adolescence, when the individual develops greater insight into their differences from others. In addition, the presentation of depression in ASDs can depend on the level of cognitive functioning in the individual, with lower functioning children displaying more behavioral issues and higher functioning children displaying more traditional depressive symptoms.
Developmental coordination disorder
The initial accounts of Asperger syndrome and other diagnostic schemes include descriptions of developmental coordination disorder. Children with ASD may be delayed in acquiring motor skills that require motor dexterity, such as bicycle riding or opening a jar, and may appear awkward or "uncomfortable in their own skin". They may be poorly coordinated, or have an odd or bouncy gait or posture, poor handwriting, or problems with visual-motor integration, visual-perceptual skills, and conceptual learning. They may show problems with proprioception (sensation of body position) on measures of developmental coordination disorder, balance, tandem gait, and finger-thumb apposition.
ASD is also associated with epilepsy, with variations in risk of epilepsy due to age, cognitive level, and type of language disorder. One in four autistic children develops seizures, often starting either in early childhood or adolescence. Seizures, caused by abnormal electrical activity in the brain, can produce a temporary loss of consciousness (a "blackout"), a body convulsion, unusual movements, or staring spells. Sometimes a contributing factor is a lack of sleep or a high fever. An EEG can help confirm the seizure's presence. Typically, onset of epilepsy occurs before age five or during puberty, and is more common in females and individuals who also have a comorbid intellectual disability.
Fragile X syndrome
Fragile X syndrome is the most common inherited form of intellectual disability. It was so named because one part of the X chromosome has a defective piece that appears pinched and fragile when under a microscope. Fragile X syndrome affects about two to five percent of people with ASD. If one child has Fragile X, there is a 50% chance that boys born to the same parents will have Fragile X (see Mendelian genetics). Other members of the family who may be contemplating having a child may also wish to be checked for the syndrome.
Gender dysphoria is a diagnosis given to people (eg transgender) who experience discomfort related to their gender identity. Autistic people are more likely to experience gender dysphoria.
The fraction of autistic individuals who also meet criteria for intellectual disability has been reported as anywhere from 25% to 70%, a wide variation illustrating the difficulty of assessing autistic intelligence. For example, a 2001 British study of 26 autistic children found about 30% with intelligence in the normal range (IQ above 70), 50% with a mild to moderate intellectual disability, and about 20% with a severe to profound intellectual disability (IQ below 35). For ASD other than autism the association is much weaker: the same study reported normal intelligence in about 94% of 53 children with PDD-NOS. Estimates are that 40–69% of individuals with ASD have some degree of an intellectual disability, with females more likely to be in severe range of an intellectual disability. Learning disabilities are also highly comorbid in individuals with an ASD. Approximately 25–75% of individuals with an ASD also have some degree of learning disability, although the types of learning disability vary depending on the specific strengths and weaknesses of the individual.
A 2006 review questioned the common assumption that most children with autism have an intellectual disability. It is possible that the association between an intellectual disability and autism is not because they usually have common causes, but because the presence of both makes it more likely that both will be diagnosed.
The CDC states that based on information from 11 reporting states 46% of people with autism have above 85 IQ.
Neuroinflammation and immune disorders
The role of the immune system and neuroinflammation in the development of autism is controversial. Until recently, there was scant evidence supporting immune hypotheses, but research into the role of immune response and neuroinflammation may have important clinical and therapeutic implications. The exact role of heightened immune response in the central nervous system (CNS) of patients with autism is uncertain, but may be a primary factor in triggering and sustaining many of the comorbid conditions associated with autism. Recent studies indicate the presence of heightened neuroimmune activity in both the brain tissue and the cerebrospinal fluid of patients with autism, supporting the view that heightened immune response may be an essential factor in the onset of autistic symptoms. A 2013 review also found evidence of microglial activation and increased cytokine production in postmortem brain samples from people with autism.
Abnormal redox metabolism
An imbalance in glutathione-dependent redox metabolism has been shown to be associated with autism spectrum disorders (ASD). Glutathione synthesis and intracellular redox balance are related to folate metabolism and methylation, metabolic pathways that have also been shown to be abnormal in ASD. Together, these metabolic abnormalities define a distinct endophenotype of TSA closely associated with genetic, epigenetic and mitochondrial abnormalities, as well as environmental factors related to ASD. Glutathione is involved in neuroprotection against oxidative stress and neuroinflammation by improving the antioxidant stress system.
In autistic children, studies have shown that glutathione metabolism can be improved. - Subcutaneously by injection of methylcobalamin. - Oral folinic acid. - A vitamin and mineral supplement that includes antioxidants, coenzyme Q10 and vitamins B. - Tetrahydrobiopterin. Interestingly, recent DBPC studies have shown that N-acetyl-1-cysteine, a glutathione precursor supplement, is effective in improving the symptoms and behaviors associated with ASD. However, glutathione was not measured in these studies.
Small, medium and large DPBC trials and open small and medium-sized clinical trials demonstrate that new treatments for children with ASD for oxidative stress are associated with improvements in baseline symptoms of ASD, sleep, gastrointestinal symptoms, hyperactivity, seizures and parental impression, sensory and motor symptoms. These new treatments include N-acetyl-l-cysteine, methylcobalamin with and without oral folinic acid, vitamin C, and a vitamin and mineral supplement that includes antioxidants, enzyme Q10, and B vitamins.
Several other treatments that have antioxidant properties, including carnosine, have also been reported to significantly improve ASD behaviors, suggesting that treatment of oxidative stress could be beneficial for children with ASD. Many antioxidants can also help improve mitochondrial function, suggesting that clinical improvements with antioxidants could occur through a reduction in oxidative stress and / or an improvement in mitochondrial function.
Abnormal folate metabolism
Several lines of evidence indicate abnormalities of folate metabolism in ASD. These abnormalities can lead to a decrease in 5-methyltetrahydrofolate production, alter the production of folate metabolites and reduce folate transport across the blood-brain barrier and in neurons. The most significant abnormalities of folate metabolism associated with ASDs may be autoantibodies to the alpha folate receptor (FRα). These autoantibodies have been associated with cerebral folate deficiency. Autoantibodies can bind to FRα and greatly impair its function.
In 2013, one study reported that 60% and 44% of 93 children with ASD were positive for FRα-blocking and binding autoantibodies, respectively. This high rate of anti-FRα autoantibody positivity was confirmed by Ramaekers et al who compared 75 children with ASD to 30 non-autistic controls with developmental delay. FRα-blocking autoantibodies were positive in 47% of children with ASD, but only in 3% of control children.
Many children with ASD and cerebral folate deficiency have marked improvements in their clinical status when taking folinic acid.
A series of five children with cerebral folate deficiency and low functioning autism with neurological deficits found a complete recovery of ASD symptoms with the use of folinic acid in a child and substantial improvements in communication in two other children.
This section needs expansion. You can help by adding to it. (November 2018)
Vitamin deficiencies are more common in autism spectrum disorders than in the general population.
- Vitamin D : In a German study, vitamin D deficiencies accounted for 78% of the cohort among an autistic hospitalized population. 52% of the ASD study population was severely impaired, which is significantly higher than in the general population. Other studies also show a higher rate of vitamin D deficiencies in ASDs. Vitamin D supplementation significantly improves some of the symptoms of autism.
- Vitamine B12 : The researchers found that, overall, B12 levels in the brain tissue of autistic children were three times lower than those of the brain tissue of children not affected by ASD. This lower-than-normal B12 profile persisted throughout life in the brain tissues of patients with autism. These deficiencies are not visible by conventional blood sampling. As for the classic deficiency of vitamin B12, it would affect up to 40% of the population, its prevalence has not yet been studied in autism spectrum disorders. Vitamin B12 deficiency is one of the most serious.
- Vitamin B9 (folic acid) : Studies have been conducted regarding folic acid supplementation in autism in children. "The results showed that folic acid supplementation significantly improved certain symptoms of autism such as sociability, verbal / preverbal cognitive language, receptive language, and emotional expression and communication. In addition, this treatment improved the concentrations of folic acid, homocysteine and redox metabolism of standardized glutathione. "
- Vitamin A : Vitamin A can induce mitochondrial dysfunction. According to a non-specific study on ASD: "Vitamin A and its derivatives, retinoids, are micronutrients necessary for the human diet in order to maintain several cellular functions of human development in adulthood as well as during aging (...) Although it is either an essential micronutrient, used in clinical applications, vitamin A has several toxic effects on the redox environment and mitochondrial function. A decline in the quality of life and an increase in the mortality rate among users of vitamin A supplements have been reported. Although the exact mechanism by which vitamin A causes its deleterious effects is not yet clear (...) Vitamin A and its derivatives, retinoids , disrupt mitochondrial function by a mechanism that is not fully understood."
- Zinc : Zinc deficiency incidence rates in children aged 0 to 3, 4 to 9 and 10 to 15 years were estimated at 43.5%, 28.1% and 3.3% for boys and at 52.5%, 28.7% and 3.5% among girls.
- Magnesium : Incidence rates of magnesium deficiency in children aged 0 to 3, 4 to 9 and 10 to 15 years were estimated at 27%, 17.1% and 4.2% for boys and at 22.9%, 12.7% and 4.3% among girls.
- Calcium : Incidence rates of calcium deficiency in children aged 0 to 3, 4 to 9 years and 10 to 15 years were estimated at 10.4%, 6.1% and 0.4% for boys and at 3.4%, 1.7% and 0.9% among girls.
Abnormalities of melatonin and circadian rhythm
Studies have found abnormalities in the physiology of melatonin and circadian rhythm in people with autism spectrum disorders (ASD). These physiological abnormalities include lower concentrations of melatonin or melatonin metabolites in ASDs compared to controls.
Nonverbal learning disorder
Psychosis and schizophrenia
Childhood-onset schizophrenia is preceded by childhood autistic spectrum disorders in almost half of cases, and an increasing number of similarities are being discovered between the two disorders.
Studies have also found that the presence of psychosis in adulthood is significantly higher in those with autism spectrum disorders, especially those with PDD-NOS, than in the general population. This psychosis generally occurs in an unusual way, with most individuals with ASD experiencing a highly atypical collection of symptoms. Recent studies have also found that the core ASD symptoms also generally present in a slightly different way during the childhood of the individuals that will later become psychotic, long before the actual psychosis develops.
The prevalence of Tourette syndrome among individuals with autism is estimated to be 6.5%, higher than the 2% to 3% prevalence for the general population. Several hypotheses for this association have been advanced, including common genetic factors and dopamine, glutamate or serotonin abnormalities.
Unusual responses to sensory stimuli are more common and prominent in individuals with autism, although there is no good evidence that sensory symptoms differentiate autism from other developmental disorders. Sensory processing disorder is comorbid with ASD, with comorbidity rates of 42–88%.
Many with ASD often find it uncomfortable to sit or stand in a way which neurotypical people will find ordinary, and will instead they may appear to be in an awkward position, such as standing with both feet together, supinating, sitting cross-legged or with one foot on top of the other or simply having an awkward gait. However, despite evidently occurring more often in people with ASD, all evidence is anecdotal and unresearched at this point. It has been observed by some psychologists that there is commonality to the way in which these 'awkward' positions may manifest.
According to one study, 35% of people with Asperger syndrome would be affected by tinnitus, which is much higher than in the general population.
Tuberous sclerosis is a rare genetic disorder that causes benign tumors to grow in the brain as well as in other vital organs. It has a consistently strong association with the autism spectrum. One to four percent of autistic people also have tuberous sclerosis. Studies have reported that between 25% and 61% of individuals with tuberous sclerosis meet the diagnostic criteria for autism with an even higher proportion showing features of a broader pervasive developmental disorder.
Sleep disorders are commonly reported by parents of individuals with ASDs, including late sleep onset, early morning awakening, and poor sleep maintenance; sleep disturbances are present in 53–78% of individuals with ASD. Unlike general pediatric insomnia, which has its roots in behavior, sleep disorders in individuals with ASD are comorbid with other neurobiological, medical, and psychiatric issues.
If not addressed, severe sleep disorders can exacerbate ASD behaviors such as self-injury; however, there are no Food and Drug Administration-approved pharmacological treatments for pediatric insomnia at this time. Some evidence suggests that melatonin supplements improve sleep patterns in children with autism but robust, high-quality studies are overall lacking.
Other mental disorders
- Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.). Washington, D.C.: American Psychiatric Association. 2000.
- Folstein SE, Rosen-Sheidley B (2001). "Genetics of autism: complex aetiology for a heterogeneous disorder". Nat Rev Genet. 2 (12): 943–955. doi:10.1038/35103559. PMID 11733747.
- Zafeiriou DI, Ververi A, Vargiami E (2007). "Childhood autism and associated comorbidities". Brain Dev (Review). 29 (5): 257–272. doi:10.1016/j.braindev.2006.09.003. PMID 17084999.
- Cuthbert, Bruce (March 1, 2013). "Overlap Blurs Diagnostic Categories – NIH-funded Study". NIMH. Archived from the original on May 10, 2015. Retrieved May 26, 2015.
National Institutes of Health-funded researchers discovered that people with disorders traditionally thought to be distinct – autism, ADHD, bipolar disorder, major depression and schizophrenia – were more likely to have suspect genetic variation at the same four chromosomal sites. These included risk versions of two genes that regulate the flow of calcium into cells.
- Johnny L. Matson; Peter Sturmey, eds. (2011). International Handbook of Autism and Pervasive Developmental Disorders. New York: Springer. pp. 53–74.
- Underwood L, McCarthy J, Tsakanikos E (September 2010). "Mental health of adults with autism spectrum disorders and intellectual disability". Curr Opin Psychiatry (Review). 23 (5): 421–426. doi:10.1097/YCO.0b013e32833cfc18. PMID 20613532.
- Siasos, G.; Tsigkou, V.; Kosmopoulos, M.; Theodosiadis, D.; Simantiris, S.; Tagkou, N. M.; Tsimpiktsioglou, A.; Stampouloglou, P. K.; Oikonomou, E.; Mourouzis, K.; Philippou, A.; Vavuranakis, M.; Stefanadis, C.; Tousoulis, D.; Papavassiliou, A. G. (2018). "Mitochondria and cardiovascular diseases—from pathophysiology to treatment". Annals of Translational Medicine. 6 (12): 256. doi:10.21037/atm.2018.06.21. PMC 6046286. PMID 30069458.
- El-Hattab AW, Scaglia F (2016). "Mitochondrial Cardiomyopathies". Front Cardiovasc Med. 3: 25. doi:10.3389/fcvm.2016.00025. PMC 4958622. PMID 27504452.
- Frye, Richard Eugene; Rossignol, Daniel A. (2014). "Treatments for Biomedical Abnormalities Associated with Autism Spectrum Disorder". Frontiers in Pediatrics. 2: 66. doi:10.3389/fped.2014.00066. PMC 4073259. PMID 25019065.
- Finsterer, Josef; Zarrouk Mahjoub, Sinda (2012). "Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders". Expert Opinion on Drug Metabolism & Toxicology. 8 (1): 71–79. doi:10.1517/17425255.2012.644535. PMID 22149023.
- Mithal, Divakar S.; Kurz, Jonathan E. (2017). "Anticonvulsant Medications in Mitochondrial Disease". Pediatric Neurology Briefs. 31 (3): 9. doi:10.15844/pedneurbriefs-31-3-3. PMC 5681459. PMID 29184381.
- Finsterer, Josef; Segall, Liane (2010). "Drugs interfering with mitochondrial disorders". Drug and Chemical Toxicology. 33 (2): 138–151. doi:10.3109/01480540903207076. PMID 19839725.
- De Oliveira, Marcos Roberto (2015). "Vitamin a and Retinoids as Mitochondrial Toxicants". Oxidative Medicine and Cellular Longevity. 2015: 1–13. doi:10.1155/2015/140267. PMC 4452429. PMID 26078802.
- White SW, Oswald D, Ollendick T, Scahill L (2009). "Anxiety in children and adolescents with autism spectrum disorders". Clin Psychol Rev. 29 (3): 216–229. doi:10.1016/j.cpr.2009.01.003. PMC 2692135. PMID 19223098.
- Reiersen AM, Todd RD (2008). "Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment". Expert Rev Neurother. 8 (4): 657–669. doi:10.1586/14737188.8.131.527. PMID 18416666.
- DSM 5 ADHD Fact Sheet Archived August 11, 2015, at the Wayback Machine
- Frye, Richard E.; Rossignol, Daniel A. (2011). "Mitochondrial Dysfunction Can Connect the Diverse Medical Symptoms Associated with Autism Spectrum Disorders". Pediatric Research. 69 (5 Part 2): 41R–47R. doi:10.1203/PDR.0b013e318212f16b. PMC 3179978. PMID 21289536.
- Luigetti, M.; Sauchelli, D.; Primiano, G.; Cuccagna, C.; Bernardo, D.; Lo Monaco, M.; Servidei, S. (2016). "Peripheral neuropathy is a common manifestation of mitochondrial diseases: A single-centre experience". European Journal of Neurology. 23 (6): 1020–1027. doi:10.1111/ene.12954. PMID 26822221.
- Luigetti, Marco; Primiano, Guido; Cuccagna, Cristina; Bernardo, Daniela; Sauchelli, Donato; Vollono, Catello; Servidei, Serenella (2018). "Small fibre neuropathy in mitochondrial diseases explored with sudoscan". Clinical Neurophysiology. 129 (8): 1618–1623. doi:10.1016/j.clinph.2018.04.755. PMID 29890373.
- McElroy SL (2004). "Diagnosing and treating comorbid (complicated) bipolar disorder". The Journal of Clinical Psychiatry. 65 Suppl 15: 35–44. PMID 15554795.
- Towbin KE, Pradella A, Gorrindo T, Pine DS, Leibenluft E (2005). "Autism spectrum traits in children with mood and anxiety disorders". Journal of Child and Adolescent Psychopharmacology (Submitted manuscript). 15 (3): 452–464. doi:10.1089/cap.2005.15.452. PMID 16092910.
- Erickson CA, Stigler KA, Corkins MR, Posey DJ, Fitzgerald JF, McDougle CJ (2005). "Gastrointestinal factors in autistic disorder: a critical review". J Autism Dev Disord. 35 (6): 713–727. doi:10.1007/s10803-005-0019-4. PMID 16267642.
- Dominus, Susan (2011-04-20). "The Crash and Burn of an Autism Guru". The New York Times.
- Encopresis Archived 2006-02-10 at the Wayback Machine, University of Iowa Health Care, Center for Disabilities and Development Archived 2006-08-16 at the Wayback Machine, accessed August 17, 2006
- Stewart, Mary; Barnard, Louise; Pearson, Joanne; Hasan, Reem; O'Brien, Gregory (2006). "Presentation of depression in autism and Asperger syndrome: A review". Autism. 10 (1): 103–116. doi:10.1177/1362361306062013. PMID 16522713.
- Ghaziuddin, Mohammad; Ghaziuddin, Neera; Greden, John (2002). "Depression in Persons with Autism: Implications for Research and Clinical Care". Journal of Autism and Developmental Disorders. Kluwer Academic Publishers-Plenum Publishers. 32 (4): 299–306. doi:10.1023/A:1016330802348. eISSN 1573-3432. hdl:2027.42/44620. ISSN 0162-3257.
- Mash EJ, Barkley RA (2003). Child Psychopathology. New York: The Guilford Press. pp. 409–454.
- McPartland J, Klin A (2006). "Asperger's syndrome". Adolesc Med Clin. 17 (3): 771–88. doi:10.1016/j.admecli.2006.06.010 (inactive 2019-07-06). PMID 17030291.
- Ehlers S, Gillberg C (1993). "The epidemiology of Asperger's syndrome. A total population study". J Child Psychol Psychiatry. 34 (8): 1327–1350. doi:10.1111/j.1469-7610.1993.tb02094.x. PMID 8294522. "Truncated version". Archived from the original on 2008-07-19. Retrieved 2008-06-15.
- Klin A (2006). "Autism and Asperger syndrome: an overview". Rev Bras Psiquiatr. 28 (suppl 1): S3–S11. doi:10.1590/S1516-44462006000500002. PMID 16791390.
- Tuchman R, Rapin I (2002). "Epilepsy in autism". Lancet Neurol. 1 (6): 352–358. doi:10.1016/S1474-4422(02)00160-6. PMID 12849396.
- "A Parent's Guide to Autism Spectrum Disorder". National Institute of Mental Health. Retrieved 17 October 2013.
- Canitano R (February 2007). "Epilepsy in autism spectrum disorders". Eur Child Adolesc Psychiatry (Review). 16 (1): 61–66. doi:10.1007/s00787-006-0563-2. PMID 16932856.
- "Autism and Fragile X Syndrome". National Fragile X Foundation. Archived from the original on 3 September 2015. Retrieved 3 November 2013.
- "Gender Dysphoria" (PDF). American Psychiatric Publishing. Retrieved April 13, 2016.
- "Gender Identity Issues Linked to Autism, ADHD". MedScape. Retrieved May 8, 2016.
- Glidden, Derek; Bouman, Walter Pierre; Jones, Bethany A.; Arcelus, Jon (2016). "Gender Dysphoria and Autism Spectrum Disorder: A Systemic Review of the Literature". Sexual Medicine Reviews. 4 (1): 3–14. doi:10.1016/j.sxmr.2015.10.003. PMID 27872002.
- de Vries, Annelou L. C.; Noens, Ilse L. J.; Cohen-Kettenis, Peggy T.; van Berckelaer-Onnes, Ina A.; Doreleijers, Theo A. (2010). "Autism Spectrum Disorders in Gender Dysphoric Children and Adolescents". Journal of Autism and Developmental Disorders. 40 (8): 930–936. doi:10.1007/s10803-010-0935-9. ISSN 0162-3257.
- Dawson M, Mottron L, Gernsbacher MA (2008). "Learning in autism" (PDF). In Byrne JH (-in-chief), Roediger HL III (vol.) (ed.). Learning and Memory: A Comprehensive Reference. 2. Academic Press. pp. 759–772. doi:10.1016/B978-012370509-9.00152-2. ISBN 978-0-12-370504-4.
- Chakrabarti S, Fombonne E (2001). "Pervasive developmental disorders in preschool children". JAMA. 285 (24): 3093–3099. doi:10.1001/jama.285.24.3093. PMID 11427137.
- O'Brien G, Pearson J (June 2004). "Autism and learning disability". Autism (Review). 8 (2): 125–140. doi:10.1177/1362361304042718. PMID 15165430.
- Edelson MG (2006). "Are the majority of children with autism mentally retarded? a systematic evaluation of the data". Focus Autism Other Dev Disabl. 21 (2): 66–83. doi:10.1177/10883576060210020301. Archived from the original on 2007-07-04. Retrieved 2007-04-15.
- Skuse DH (2007). "Rethinking the nature of genetic vulnerability to autistic spectrum disorders". Trends Genet. 23 (8): 387–395. doi:10.1016/j.tig.2007.06.003. PMID 17630015.
- "Diseases & Conditions | Features | CDC". 2018-04-04.
- Pardo CA, Vargas DL, Zimmerman AW (December 2005). "Immunity, neuroglia and neuroinflammation in autism". Int Rev Psychiatry. 17 (6): 485–95. CiteSeerX 10.1.1.504.8397. doi:10.1080/02646830500381930. PMID 16401547.
- Gesundheit B, Rosenzweig JP, Naor D, et al. (August 2013). "Immunological and autoimmune considerations of Autism Spectrum Disorders". J. Autoimmun. 44: 1–7. doi:10.1016/j.jaut.2013.05.005. PMID 23867105.
- Ghanizadeh, A.; Akhondzadeh, S.; Hormozi, M.; Makarem, A.; Abotorabi-Zarchi, M.; Firoozabadi, A. (2012). "Glutathione-Related Factors and Oxidative Stress in Autism, A Review". Current Medicinal Chemistry. 19 (23): 4000–4005. doi:10.2174/092986712802002572.
- Endres, Dominique; Dersch, Rick; Stich, Oliver; Buchwald, Armin; Perlov, Evgeniy; Feige, Bernd; Maier, Simon; Riedel, Andreas; Van Elst, Ludger Tebartz (2016). "Vitamin D Deficiency in Adult Patients with Schizophreniform and Autism Spectrum Syndromes: A One-Year Cohort Study at a German Tertiary Care Hospital". Frontiers in Psychiatry. 7: 168. doi:10.3389/fpsyt.2016.00168. PMC 5052261. PMID 27766084.
- Saad, Khaled; Abdel-Rahman, Ahmed A.; Elserogy, Yasser M.; Al-Atram, Abdulrahman A.; El-Houfey, Amira A.; Othman, Hisham A. -K.; Bjørklund, Geir; Jia, Feiyong; Urbina, Mauricio A.; Abo-Elela, Mohamed Gamil M.; Ahmad, Faisal-Alkhateeb; Abd El-Baseer, Khaled A.; Ahmed, Ahmed E.; Abdel-Salam, Ahmad M. (2018). "Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder". Journal of Child Psychology and Psychiatry. 59 (1): 20–29. doi:10.1111/jcpp.12652. PMID 27868194.
- "Science Blog | Autism Speaks".
- Zhang, Yiting; Hodgson, Nathaniel W.; Trivedi, Malav S.; Abdolmaleky, Hamid M.; Fournier, Margot; Cuenod, Michel; Do, Kim Quang; Deth, Richard C. (2016). "Decreased Brain Levels of Vitamin B12 in Aging, Autism and Schizophrenia". PLOS ONE. 11 (1): e0146797. Bibcode:2016PLoSO..1146797Z. doi:10.1371/journal.pone.0146797. PMC 4723262. PMID 26799654.
- "B12 Deficiency May be More Widespread Than Thought : USDA ARS".
- Sun, Caihong; Zou, Mingyang; Zhao, Dong; Xia, Wei; Wu, Lijie (2016). "Efficacy of Folic Acid Supplementation in Autistic Children Participating in Structured Teaching: An Open-Label Trial". Nutrients. 8 (6): 337. doi:10.3390/nu8060337. PMC 4924178. PMID 27338456.
- Frye, R. E.; Slattery, J.; Delhey, L.; Furgerson, B.; Strickland, T.; Tippett, M.; Sailey, A.; Wynne, R.; Rose, S.; Melnyk, S.; Jill James, S.; Sequeira, J. M.; Quadros, E. V. (2018). "Folinic acid improves verbal communication in children with autism and language impairment: A randomized double-blind placebo-controlled trial". Molecular Psychiatry. 23 (2): 247–256. doi:10.1038/mp.2016.168. PMC 5794882. PMID 27752075.
- Yasuda, Hiroshi; Tsutsui, Toyoharu (2013). "Assessment of Infantile Mineral Imbalances in Autism Spectrum Disorders (ASDs)". International Journal of Environmental Research and Public Health. 10 (11): 6027–6043. doi:10.3390/ijerph10116027. PMC 3863885. PMID 24284360.
- "For kids with autism, supplements often result in nutrient imbalances".
- Stewart, Patricia A.; Hyman, Susan L.; Schmidt, Brianne L.; MacKlin, Eric A.; Reynolds, Ann; Johnson, Cynthia R.; James, S. Jill; Manning-Courtney, Patricia (2015). "Dietary Supplementation in Children with Autism Spectrum Disorders: Common, Insufficient, and Excessive". Journal of the Academy of Nutrition and Dietetics. 115 (8): 1237–1248. doi:10.1016/j.jand.2015.03.026. PMID 26052041.
- Russell, A. J.; Jassi, A.; Fullana, M. A.; Mack, H.; Johnston, K.; Heyman, I.; Murphy, D. G.; Mataix-Cols, D. (2013). "Cognitive Behavior Therapy for Comorbid Obsessive-Compulsive Disorder in High-Functioning Autism Spectrum Disorders: A Randomized Controlled Trial" (PDF). Depression and Anxiety. 30 (8): 697–708. doi:10.1002/da.22053. PMID 23389964.
- Rapoport, Judith; Chavez, Alex; Greenstein, Deanna; Addington, Anjene; Gogtay, Nitin (2009). "Autism-Spectrum Disorders and Childhood Onset Schizophrenia: Clinical and Biological Contributions to a Relationship Revisited". Journal of the American Academy of Child and Adolescent Psychiatry. 48 (1): 10–18. doi:10.1097/CHI.0b013e31818b1c63. PMC 2664646. PMID 19218893.
- Mourisden; Rich; Isager (2008). "Psychiatric disorders in adults diagnosed as children with atypical autism. A case control study". Journal of Neural Transmission. 115 (1): 135–138. doi:10.1007/s00702-007-0798-1. PMID 17768593.
- Larson, Felicity; Wagner, Adam; Jones, Peter; Tantam, Digby; Lai, Meng-Chuan; Baron-Cohen, Simon; Holland, Anthony (2016). "Psychosis in autism: comparison of the features of both conditions in a dually affected cohort". The British Journal of Psychiatry. 210 (4): 269–275. doi:10.1192/bjp.bp.116.187682. PMC 5376719. PMID 27979819.
- Rogers SJ, Ozonoff S (2005). "Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence". J Child Psychol Psychiatry. 46 (12): 1255–1268. doi:10.1111/j.1469-7610.2005.01431.x. PMID 16313426.
- Baranek GT (October 2002). "Efficacy of sensory and motor interventions for children with autism". J Autism Dev Disord (Review). 32 (5): 397–422. doi:10.1023/A:1020541906063. PMID 12463517.
- Ming X, Brimacombe M, Wagner GC (2007). "Prevalence of motor impairment in autism spectrum disorders". Brain Dev. 29 (9): 565–570. doi:10.1016/j.braindev.2007.03.002. PMID 17467940.
- Carry Terra, Adults on the Spectrum: These are your Feet on Asperger's http://www.aspiestrategy.com/2013/02/adults-on-spectrum-these-are-your-feet.html?m=1
- Danesh, Ali A.; Lang, Dustin; Kaf, Wafaa; Andreassen, William D.; Scott, Jack; Eshraghi, Adrien A. (2015). "Tinnitus and hyperacusis in autism spectrum disorders with emphasis on high functioning individuals diagnosed with Asperger's Syndrome". International Journal of Pediatric Otorhinolaryngology. 79 (10): 1683–1688. doi:10.1016/j.ijporl.2015.07.024. PMID 26243502.
- Smalley, S. L. (1998). "Autism and tuberous sclerosis". Journal of Autism and Developmental Disorders. 28 (5): 407–414. doi:10.1023/A:1026052421693. PMID 9813776.
- Harrison JE, Bolton, PF (1997). "Annotation: Tuberous sclerosis". Journal of Child Psychology and Psychiatry. 38 (6): 603–614. doi:10.1111/j.1469-7610.1997.tb01687.x. PMID 9315970.
- Malow BA, Byars K, Johnson K, et al. (1 November 2012). "A Practice Pathway for the Identification, Evaluation, and Management of Insomnia in Children and Adolescents With Autism Spectrum Disorders". Pediatrics. 130 (S2): S106–S124. doi:10.1542/peds.2012-0900I. PMID 23118242.
- "Poor sleep in children with autism associated with problematic behavior during the day". Truthly. Archived from the original on 5 February 2015. Retrieved 5 February 2015.
- Johnson, Kyle P.; Malow, Beth P. (1 October 2008). "Assessment and Pharmacologic Treatment of Sleep Disturbance in Autism". Child and Adolescent Psychiatric Clinics of North America. 17 (4): 773–785. doi:10.1016/j.chc.2008.06.006. PMID 18775369.
- "Melatonin supplementation associated with improved sleep and behavior in children with autism". Truthly. Archived from the original on 5 February 2015. Retrieved 5 February 2015.
- "More Evidence that Melatonin Eases Autism-Associated Insomnia". Autism Speaks. Retrieved 5 February 2015.
- Matson JL, Nebel-Schwalm MS (2007). "Comorbid psychopathology with autism spectrum disorder in children: an overview". Res Dev Disabil. 28 (4): 341–352. CiteSeerX 10.1.1.697.4938. doi:10.1016/j.ridd.2005.12.004. PMID 16765022.